CPG 7909
Sponsors
Pfizer, Ronald Levy, Stanford University, University of Iowa, National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
Bacterial SepsisCOVID-19Carcinoma, Metastatic BreastCarcinoma, Non-Small Cell LungCarcinoma, Renal CellChronic Lymphocytic LeukemiaMalariaMycosis Fungoides
Phase 1
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
CompletedNCT00031278
Start: 2001-10-31End: 2003-06-30Updated: 2011-05-30
CPG 7909 in Patients Wih Stage IV Renal Cell Cancer
CompletedNCT00043407
Start: 2002-03-31End: 2004-09-30Updated: 2009-02-12
CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
CompletedNCT00185965
Start: 2004-07-31End: 2010-03-31Updated: 2014-08-01
Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.
WithdrawnNCT00226993
Start: 2005-03-31Updated: 2016-12-01
A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated
CompletedNCT00233506
Start: 2004-07-31End: 2011-06-30Updated: 2017-02-06
Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant
CompletedNCT00320658
Start: 2006-03-31End: 2007-07-31Updated: 2008-01-21
Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant
TerminatedNCT01164514
Start: 2011-11-30End: 2013-02-28Updated: 2014-01-31
A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
RecruitingNCT07221162
Start: 2025-12-05End: 2026-11-24Target: 140Updated: 2026-04-03